These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31877199)

  • 21. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.
    Marra F; Marra CA; Bruchet N; Richardson K; Moadebi S; Elwood RK; Fitzgerald JM
    Int J Tuberc Lung Dis; 2007 Aug; 11(8):868-75. PubMed ID: 17705952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2020 Dec; 111(1):61-67. PubMed ID: 33404008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.
    Zhang SY; Fu JY; Guo XY; Wu DZ; Zhang T; Li C; Qiu L; Shao CR; Xiao HP; Chu NH; Deng QY; Zhang X; Yan XF; Wang ZL; Zhang ZJ; Jiang X; Zheng YJ; Zheng PY; Zhang HY; Lu ZH
    Infect Dis Poverty; 2020 May; 9(1):50. PubMed ID: 32381098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.
    Jones J; Mudaly V; Voget J; Naledi T; Maartens G; Cohen K
    BMC Infect Dis; 2019 Jun; 19(1):544. PubMed ID: 31221100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana.
    Amalba A; Bugri AA
    Pan Afr Med J; 2021; 38():191. PubMed ID: 33995797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study.
    Siddiqui AN; Khayyam KU; Sharma M
    Biomed Res Int; 2016; 2016():7273935. PubMed ID: 27642601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil.
    Vieira DE; Gomes M
    J Bras Pneumol; 2008 Dec; 34(12):1049-55. PubMed ID: 19180340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse Drug Reaction Patterns of First-line Anti-tubercular Drugs among Saharia Tuberculosis Patients: An Observational Study in Particularly Vulnerable Tribal Group of Madhya Pradesh, India.
    Mishra P; Bhat J; Yadav R; Sharma RK; Rao VG
    Indian J Public Health; 2023 Oct; 67(4):542-545. PubMed ID: 38934815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse drug reactions in tuberculosis and management.
    Prasad R; Singh A; Gupta N
    Indian J Tuberc; 2019 Oct; 66(4):520-532. PubMed ID: 31813444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study.
    Rousset S; Lafaurie M; Guet-Revillet H; Protin C; Le Grusse J; Derumeaux H; Gandia P; Nourhashemi F; Sailler L; Sommet A; Delobel P; Martin-Blondel G
    Drugs Aging; 2021 Jan; 38(1):43-52. PubMed ID: 33145702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levofloxacin treatment of active tuberculosis and the risk of adverse events.
    Marra F; Marra CA; Moadebi S; Shi P; Elwood RK; Stark G; FitzGerald JM
    Chest; 2005 Sep; 128(3):1406-13. PubMed ID: 16162736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allergy to anti-tuberculosis treatment: Place of reintroduction drug test.
    Smadhi H; Ben Saad S; Daghfous H; Ben Mansour A; Tritar F
    Tunis Med; 2019 Mar; 97(3):484-490. PubMed ID: 31729724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis.
    Kwon BS; Kim Y; Lee SH; Lim SY; Lee YJ; Park JS; Cho YJ; Yoon HI; Lee CT; Lee JH
    PLoS One; 2020; 15(7):e0236109. PubMed ID: 32692774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.
    Chung SJ; Byeon SJ; Choi JH
    J Korean Med Sci; 2022 Apr; 37(16):e128. PubMed ID: 35470602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports.
    Njuguna C; Stewart A; Mouton JP; Blockman M; Maartens G; Swart A; Chisholm B; Jones J; Dheda M; Igumbor EU; Cohen K
    Drug Saf; 2016 Feb; 39(2):159-69. PubMed ID: 26547719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.